Immatics N.V. (IMTX) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immatics N.V. is the larger company by market cap ($1.10 billion vs $833.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | ODTX |
|---|---|---|
| Share price | $7.26 | $17.35 |
| Market cap | $1.10B | $833.82M |
| 1-day change | -2.60% | -4.04% |
| YTD return | -29.05% | — |
| 1-year return | -20.83% | — |
| 5-year return | -46.21% | — |
| EPS (TTM) | $-1.87 | $-7.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.41 | $29.05 |
| 52-week low | $7.22 | $15.10 |
| Distance from 52-week high | -41.53% | -40.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +142.97% | +106.05% |
| Average volume | 595.07K | 270.92K |
| Shares outstanding | 152.23M | 48.06M |
| Employees | 704 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
IMTX vs ODTX FAQ
Which is bigger, Immatics N.V. or Odyssey Therapeutics?
Immatics N.V. (IMTX) is larger, with a market capitalization of $1.10B compared with $833.82M for Odyssey Therapeutics (ODTX).
Are Immatics N.V. and Odyssey Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.